Navigation Links
Conatus Pharmaceuticals Initiates a Phase 2 Clinical Trial for the Treatment of Hepatitis
Date:12/20/2007

SAN DIEGO, Dec. 20 /PRNewswire/ -- Conatus Pharmaceuticals Inc. today announced the initiation of a clinical trial with a novel drug candidate for the treatment of liver disease associated with Hepatitis C Virus (HCV) infection in patients who have failed the approved standard of care treatments.

The oral, small molecule drug candidate, CTS-1027, is being studied as a treatment for the inflammatory damage to the liver resulting from infection by HCV. CTS-1027 inhibits the activity of key members of a class of protease enzymes, the matrix metalloproteinases or MMPs. In the liver and in other solid organs, MMPs play an important role in regulating inflammation as well as in maintaining the integrity of the extracellular matrix. CTS-1027 has been shown to be effective in multiple preclinical models of liver disease.

The clinical trial is a double-blind, placebo-controlled, multiple-dose trial lasting for four weeks followed by a voluntary open label period of up to eight additional weeks. The Company expects approximately 100 patients to be enrolled. The clinical trial will be conducted at up to ten medical centers in the U.S. Additional information about the trial can be found at http://www.clinicaltrials.gov (Identifier NCT00570336) or http://clinicaltrials.gov/ct2/show/NCT00570336?term=CTS-1027&rank=1.

"We are excited to initiate this proof of concept trial in HCV patients with CTS-1027," said Steven J. Mento, President and CEO of Conatus. "We believe that CTS-1027 represents a novel approach to treating liver inflammation and look forward to developing this drug candidate to fill an important medical need in HCV-infected patients."

Conatus Pharmaceuticals Inc. is a privately-held specialty pharmaceutical company engaged in the development of innovative human therapeutics to treat
'/>"/>

SOURCE Conatus Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)WALTHAM, Mass., Dec. 3 Inverness Medical Innovations, Inc. (NYSE: IMA ), a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and h
(Date:12/2/2009)NEW YORK, Dec. 2 Reportlinker.com announces that a new market research report is available in its catalogue: ,, Neurostimulation - A Global Market Perspective ,, http://www.reportlinker.com/p01642
(Date:12/2/2009)TUSTIN, Calif., Dec. 2 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today reported completion of patient enrollment in a dose confirmation and dosimetry trial of Cotara® in patients with rel
(Date:12/2/2009)JERUSALEM, Israel, December 2 Gamida Cell announced today,a feasibility study evaluating the preclinical (animal study) safety and,efficacy of a gene therapy product which combines technology from We
Breaking Biology Technology:Reportlinker Adds Neurostimulation - A Global Market Perspective 2Reportlinker Adds Neurostimulation - A Global Market Perspective 3Reportlinker Adds Neurostimulation - A Global Market Perspective 4Reportlinker Adds Neurostimulation - A Global Market Perspective 5Reportlinker Adds Neurostimulation - A Global Market Perspective 6Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 2Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 3
...barely cover a human thumbnail, but they can hold ...cause this emerging technology offers a view of so...ct for studying relationships among the 30,000 gen... next major mysteries. , ,Biochips, essentially sl...m, give scientists a chance to look at bits of DNA...
... Computer Systems unit of Milwaukee-based Fiserv ...offer a product that verifies customers, identitie...nsightID provides access to billions of public rec...der of banking technology, and InsightAmerica, a s...nce to help prevent fraud losses from identity the...
...Sensient Technologies Corp. (NYSE:SXT) reported $...ues for its first quarter ended March 31. Diluted ...obal manufacturer and marketer of colors, flavors ...ce the same quarter last year. Total debt was $596... for the first quarter include a one-time expense ...
Other Biology Technology:Madison biochip research offers geneticists a big view through a small window 2Madison biochip research offers geneticists a big view through a small window 3
(Date:12/2/2009)...acculturated Latino men have a more difficult time...ated to U.S. culture, but acculturation has no aff...f these findings are published in Cancer Epidemio...merican Association for Cancer Research. The Decem...lturation affects smoking cessation differently fo...
(Date:12/2/2009)...e who smoke their first cigarette within minutes a..., a by-product of nicotine when processed by the b...he number of cigarettes smoked. , "Since cotin...er, our results suggest that smokers who smoke imm...r lung cancer," said researcher Joshua E. Muscat, ...
(Date:12/2/2009)...nce of a cancer-free status did not prompt people ...hy (CT) lung-cancer screening program to pick up t...y published in Cancer Epidemiology, Biomarkers & ... for Cancer Research. The December issue contains ...ld negate widespread concern in the lung screening...
Breaking Biology News(10 mins):Acculturation affects smoking cessation success among Latinos 2Increased nicotine levels detected in those who light-up earlier 2Repeat negative CT scan for lung cancer does not encourage ex-smokers to resume the habit 2Advanced Heart Procedure Treats Growing Problem 51120 1Advanced Heart Procedure Treats Growing Problem 51120 2Advanced Heart Procedure Treats Growing Problem 51120 3Screen All Newborns for Hip Dysplasia Study Urges 51115 1Screen All Newborns for Hip Dysplasia Study Urges 51115 2B Line Medical 28R 29 and Surgical Science Sign Data Integration Agreement for LapSim 28R 29 Simulator 51109 1B Line Medical 28R 29 and Surgical Science Sign Data Integration Agreement for LapSim 28R 29 Simulator 51109 2B Line Medical 28R 29 and Surgical Science Sign Data Integration Agreement for LapSim 28R 29 Simulator 51109 3B Line Medical 28R 29 and Surgical Science Sign Data Integration Agreement for LapSim 28R 29 Simulator 51109 4B Line Medical 28R 29 and Surgical Science Sign Data Integration Agreement for LapSim 28R 29 Simulator 51109 5B Line Medical 28R 29 and Surgical Science Sign Data Integration Agreement for LapSim 28R 29 Simulator 51109 6
...rding to scientific gospel, social behavior is dic...as food, territory and reproduction. , That may we...breaking study researchers from the University of ...interactions among young mice result from basic mo... researchers say, the extent of a young mouse,s gr...
... fruit fly is able to locate and blissfully drown ...ially since its flight path seems to be so erratic...dy Reynolds at Rothamsted Research in the United K...Fruit flies explore their environment using a seri...° body-saccades. Some of these manoeuvres avoid ob...
...ts to developing new antibiotics, and a technique ...locking those secrets. , That,s the view of Unive...y, who will discuss his group,s progress toward th...ysical Society in Baltimore, Md. , Ramamoorthy,...re the germ-killing properties of natural antibiot...
Other Biology News:In young mice, gregariousness seems to reside in the genes 2In young mice, gregariousness seems to reside in the genes 3Flies don't buzz about aimlessly! 2Natural antibiotics yield secrets to atom-level imaging technique 2Natural antibiotics yield secrets to atom-level imaging technique 3
...The CopyControl™ vector can be induced prior t...ctors provide the stability of single-copy BACs wi...r cloning vectors. The kits provide the linearized..., insert size screening system) necessary to creat...
Cell Wall Degrading Enzyme Complex Aspergillus sp. from Sigma-Aldrich
...Templates rich in GC content or with significant s...lify, and when subjected to PCR result in little o...an be increased by the addition of enhancing agent...an effective PCR enhancer for GC-rich templates.,...
...Application: The simple three step procedure (PCR,...sformation) can be completed in one day. The typic... than 80%. , Features and Benefits: , , Universal ...ector , High Cloning Efficiency - Typically>80% , ...
Biology Products: